Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
Public ClinicalTrials.gov record NCT00673179. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Outpatient Chemotherapy in Pediatric Osteosarcoma: Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical research study is to learn if giving certain combinations of chemotherapy drugs before and after surgery, mostly in the outpatient clinic instead of in the hospital, can result in fewer hospital stays during treatment for osteosarcoma. The drugs and schedules will vary depending on the status of the cancer and its level of risk for spreading, but they will include combinations of doxorubicin (non-liposomal), cisplatin, methotrexate, and ifosfamide, as described below.
Study identification
- NCT ID
- NCT00673179
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 7 participants
Conditions and interventions
Conditions
Interventions
- Doxorubicin Drug
- Cisplatin Drug
- Methotrexate Drug
- Leucovorin Drug
- Dexrazoxane Drug
- Ifosfamide Drug
- Questionnaire Behavioral
- Gemcitabine Drug
- Sargramostim Drug
- Surgery Procedure
- Mesna Drug
Drug · Behavioral · Procedure
Eligibility (public fields only)
- Age range
- 5 Years to 40 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2008
- Primary completion
- Oct 31, 2010
- Completion
- Oct 31, 2010
- Last update posted
- Sep 9, 2014
2008 – 2010
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UT MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Osteosarcoma trials
Other public records listing Osteosarcoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT05235165: Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma Recruiting
- NCT05227326: AOH1996 for the Treatment of Refractory Solid Tumors Recruiting
- NCT04616560: Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor Recruiting
- NCT07725380: Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma Recruiting
- NCT07321912: Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma Recruiting
- NCT03900793: Losartan + Sunitinib in Treatment of Osteosarcoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00673179, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2014 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00673179 live on ClinicalTrials.gov.